News & Events Upcoming events Oct 21, 2026 - Oct 23, 2026 MSToronto 2026 - 10th Joint ACTRIMS-ECTRIMS Meeting Toronto, Canada More info and meet us there Nov 16, 2026 - Nov 19, 2026 MEDICA 2026 Düsseldorf, Germany More info and meet us there Nov 16, 2026 - Nov 19, 2026 19th Clinical Trials on Alzheimer's Disease (CTAD) Boston, MA, United States of America More info and meet us there See all upcoming events Latest news May 1, 2018 Fujirebio enters into agreement with Janssen Pharmaceuticals to develop and commercialize AMYLOID β 42/40 RATIO assay Read more Sep 4, 2017 Morphotek®, Inc. Announces an Agreement With Fujirebio Diagnostics, Inc to commercialize the CA125 II Assay as a Companion Diagnostic for Farletuzumab® Read more Nov 13, 2016 Fujirebio becomes a Sustaining Member of APHL Read more May 10, 2015 LUMIPULSE® G1200 now available in the United States Read more Oct 1, 2013 Miraca Holdings announces name change of Innogenetics to Fujirebio Europe Read more Nov 30, 2011 Fujirebio Diagnostics, Inc. Named the #6 Best Place to Work in PA 2011 Read more Load More
Oct 21, 2026 - Oct 23, 2026 MSToronto 2026 - 10th Joint ACTRIMS-ECTRIMS Meeting Toronto, Canada More info and meet us there
Nov 16, 2026 - Nov 19, 2026 19th Clinical Trials on Alzheimer's Disease (CTAD) Boston, MA, United States of America More info and meet us there
May 1, 2018 Fujirebio enters into agreement with Janssen Pharmaceuticals to develop and commercialize AMYLOID β 42/40 RATIO assay Read more
Sep 4, 2017 Morphotek®, Inc. Announces an Agreement With Fujirebio Diagnostics, Inc to commercialize the CA125 II Assay as a Companion Diagnostic for Farletuzumab® Read more
